drugset / Trial / NCT00671034

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized clinical trial is studying giving calaspargase pegol together with combination chemotherapy to see how well it works compared with giving pegaspargase together with combination chemotherapy in treating younger patients with newly diagnosed high-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

Timeline

Start
2008-07-21
Primary completion
2011-02-01
Completion
2021-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Calaspargase Pegol Protein / enzyme biologic Intravenous
Subject Pegaspargase Protein / enzyme biologic Intravenous
Background Cyclophosphamide Other / unclassified Intravenous
Background Cytarabine Small molecule Intravenous
Background Daunorubicin Small molecule Intravenous
Background Dexamethasone Small molecule Oral
Background Doxorubicin Other / unclassified Intravenous
Background MERCAPTOPURINE ANHYDROUS Small molecule Oral
Background Methotrexate Small molecule Intravenous
Background Prednisone Other / unclassified Intravenous
Background Thioguanine Small molecule Oral
Background Vincristine Small molecule Intravenous